Cell Therapy Collaboration and Licensing Deals 2016-2024


Cell Therapy Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 910 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cell therapy dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse cell therapy collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Cell Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cell therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Cell Therapy Collaboration and Licensing Deals includes:
•    Trends in cell therapy dealmaking in the biopharma industry
•    Directory of cell therapy deal records covering pharmaceutical and biotechnology
•    The leading cell therapy deals by value
•    Most active cell therapy licensing dealmakers

Cell Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse cell therapy collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in cell therapy dealmaking
2.1. Introduction
2.2. Cell therapy deals over the years
2.3. Most active cell therapy dealmakers
2.4. Cell therapy deals by deal type
2.5. Cell therapy deals by therapy area
2.6. Cell therapy deals by industry sector
2.7. Deal terms for cell therapy deals
2.7.1 Cell therapy deals headline values
2.7.2 Cell therapy deal upfront payments
2.7.3 Cell therapy deal milestone payments
2.7.4 Cell therapy royalty rates

Chapter 3 – Leading cell therapy deals
3.1. Introduction
3.2. Top cell therapy deals by value

Chapter 4 – Most active cell therapy dealmakers
4.1. Introduction
4.2. Most active cell therapy dealmakers
4.3. Most active cell therapy deals company profiles

Chapter 5 – Cell therapy contracts dealmaking directory
5.1. Introduction
5.2. Cell therapy contracts dealmaking directory

Chapter 6 – Cell therapy dealmaking by technology type

Deal directory

Deal directory – Cell therapy deals by company A-Z
Deal directory – Cell therapy deals by deal type
Deal directory – Cell therapy deals by therapy area

Deal type definitions

About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Cell therapy deals since 2016
Figure 2: Active cell therapy dealmaking activity – 2016 - 2024
Figure 3: Cell therapy deals by deal type since 2016
Figure 4: Cell therapy deals by therapy area since 2016
Figure 5: Cell therapy deals by industry sector since 2016
Figure 6: Cell therapy deals with a headline value
Figure 7: Cell therapy deals with an upfront value
Figure 8: Cell therapy deals with a milestone value
Figure 9: Cell therapy deals with a royalty rate value
Figure 10: Top cell therapy deals by value since 2016
Figure 11: Most active cell therapy dealmakers 2016 - 2024
Figure 12: Cell therapy deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2seventy bio, 3D Medicines, 3SBio, 4basebio Discovery, 908 Devices, A*STAR Agency for Science, Technology and Research, A*STAR’ Institute of Molecular and Cell Biology, A2 Biotherapeutics, Abbvie, AbCellera Biologics, AbelZeta Pharma, Abingworth Management, Abintus Bio, Abound Bio, Abu Dhabi Stem Cells Center, Abveris, Abzena, Accellix, ACEA Biosciences, Acepodia, aCGT Vector, Achilles Therapeutics, Actinium Pharmaceuticals, ACT Therapeutics, ActualEyes, AdAlta, Adaptimmune, Adaptive Biotechnologies, Adicet Bio, Adva Biotechnology, Advanced Biological Innovation and Manufacturing, Advanced Regenerative Manufacturing Institute, Aethon Therapeutics, Affimed Therapeutics, Affini-T Therapeutics, AffyXell Therapeutics, AGC Biologics, Agenus Bio, AgeX Therapeutics, AgonOx, AiVita Biomedical, Akoya Biosciences, Akron BioProducts, Alaya.bio, Alder Therapeutics, Aleta Biotherapeutics, Allele Biotechnology and Pharmaceuticals, Alliance for Cancer Gene Therapy, Alliance for Regenerative Medicine, Allogene Overland Biopharm, Allogene Therapeutics, Alloplex Biotherapeutics, AlloVir, Alpha Biopharma, Alphageneron Pharmaceuticals, Alpine Immune Sciences, Altor BioScience, ALTuCELL, Ambys Medicines, American CryoStem, American National Multiple Sclerosis Society, Amgen, Anagenesis Biotechnologies, Anew Medical, Ankarys Therapeutics, Antengene, Anthony Nolan, Antion Biosciences, Apeiron Biologics, Appia Bio, Applied Cells, Applied StemCell, Aquitaine Science Transfert (SATT Aquitaine), Arbele, Arbor Biotechnologies, Arcellx, Arctic Vision, Arovella Therapeutics, Arsenal Biosciences, Artisan Bio, Artiva Biotherapeutics, Asahi Kasei, Ascenion, ASC Therapeutics, Asklepios Biopharmaceutical, Astellas Institute for Regenerative Medicine, Astellas Pharma, Astellas Pharma US, Asterias Biotherapeutics, AstraZeneca, Atara Biotherapeutics, Atelerix, Athenex, Athersys, ATMPS, ATP, Atvio Biotech, Autolomous, Autolus, Avacta, Avactis Biosciences, Avalon GloboCare, Avance Biosciences, Avectas, Avery Therapeutics, Avid Bioservices, Avita Therapeutics, Axis Therapeutics, B-MoGen Biotechnologies, Banner MD Anderson Cancer Center, Baxalta, Bayer, Baylor College of Medicine, Beam Therapeutics, Be Biopharma, Beckman Research Institute of City of Hope, BeiGene, Bellicum Pharmaceuticals, Ben-Gurion University, Benaroya Research Institute, Bennu Pharmaceuticals, Be The Match BioTherapies, Beverly Hills Cancer Center, Bill and Melinda Gates Foundation, Bio-Techne, BioAtla, BioCardia, BioCentriq, BiocurePharm, Biocytogen, BioLamina, BioLife Solutions, biologistex CCM, BioMagnetic Solutions, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, BioNex Solutions, Bionomics, Bionoveo, BioNTech, BioRestorative Therapies, Biosceptre International, BioSenic, Biositu Pharmaceutical Technology, Biosolution, BioSpherix, BioTherapeutic Labs, BioVectra, BIRAD Research and Development Company, Bird Foundation, Bit Bio, Bluebird Bio, Bluebridge Technologies, BlueRock Therapeutics, Bone Therapeutics, Bpifrance, BrainStorm Cell Therapeutics, BriaCell Therapeutics, Brigham and Women's Hospital, BrightPath Biotherapeutics, Bristol-Myers Squibb, BRL Medicine, Brooklyn ImmunoTherapeutics, C3i, Cabaletta Bio, Caladrius Biosciences, Calidi Biotherapeutics, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Cancer Research UK, Candel Therapeutics, Capricor Therapeutics, Captivate Bio, Caravan Biologix, Caribou Biosciences, Carina Biotech, Caring Cross, Carisma Therapeutics, Carolina BioOncology Institute, CARsgen, Cartherics, Casebia Therapeutics, Case Western Reserve University, CASI Pharmaceuticals, Catalent, Catamaran Bio, Catholic University Leuven, CavoGene LifeSciences, CDISC, Celdara Medical, Celest Therapeutics, Celgene, Cell-Easy, Cell2in, Cell and Gene Therapy Catapult, Cellares, Cell Cure Neurosciences, Cell Design Labs, Cellect Biotechnology, Cellectis, Cellenkos, Cellevolve Bio, CellGenix, Cellinfinity Bio, Cellipont Bioservices, Cellistic, Cell Medica, Cell Mogrify, Cell One Partners, CellOrigin Biotech, Cell Point, CellPoint, CellSpring, Cellthera Pharma, Cell Therapy Catapult, Cell Therapy Manufacturing Center, Cellular Biomedicine, Cellular Engineering Technologies, Cellular Origins, Cellusion, Cellvation, Celregen, Celsius Therapeutics, Celularity, Celyad, Center for Breakthrough Medicines, Center for International Blood and Marrow Transplant Research, Centre for Commercialization of Regenerative Medicine (CCRM), Century Therapeutics, CERo Therapeutics, Certara, Cevec Pharmaceuticals, CGT Global, Champions Oncology, Charite Universitatsmedizin Berlin, Charles River Laboratories, Chart Industries, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's National Hospital, Chimeric Therapeutics, China Medical System, Chinese University of Hong Kong, Cimeio Therapeutics, Citius Pharmaceuticals, City of Hope, Cleara Biotech, Coeptis Therapeutics, Cognate BioServices, CoImmune, Columbia University, Conkwest, Cooperative Research Centre for Cell Therapy Manufacturing, Corestem, CRISPR Therapeutics, CryoPort, CSafe Global, CTMC, Cue Biopharma, Curate Biosciences, CureCell, Curiox Biosystems, Cytea Bio, Cytiva, Cyto-care, CytoImmune Therapeutics, CytoLynx Therapeutics, CytoMed Therapeutics, CytoSen Therapeutics, Cytovant Sciences, CYTOVIA Therapeutics, DAAN Bio Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dana-Farber Cancer Institute, Danaher, DanausGT Biotechnology, Dartmouth College, Deepcell, Dendreon, Department of Defense, Deverra Therapeutics, Diakonos Oncology, DigiLab, Diomics, DNA Script, Dragonfly Therapeutics, Duke-NUS Graduate Medical School Singapore, Duke University, DuPont Pioneer, EdiGene, Editas Medicine, Edith Wolfson Medical Center, eGenesis, Egle Therapeutics, ElevateBio, Elicio Therapeutics, Eli Lilly, Elixirgen, Elpis Biomed, Embleema, Emercell, Endocyte, Enlivex, ENPICOM, Enterprise Ireland, Entrada Therapeutics, eQcell, Erasmus University Medical Center, ERS Genomics, Erytech Pharma, Eterna Therapeutics, Eureka Eurostars, Eureka Therapeutics, European Wellness Biomedical Group, Eutilogics, EverCell Bio, Evercyte, EvolveImmune Therapeutics, Evotec, Exacis Biotherapeutics, ExcellaBio, ExCellThera, ExonanoRNA, Exopharm, Experimental Drug Development Centre, Exploit Technologies, F1 Oncology, Factor Bioscience, Fate Therapeutics, Feinstein Institute for Medical Research, Feldan Therapeutics, Ferring Pharmaceuticals, FibroBiologics, FibroGenesis, FineImmune Biotechnology, FloDesign Sonics, Fluidigm, Food and Drug Administration (FDA), Formula Pharmaceuticals, Fortress Biotech, Forty Seven, Fosun Pharmaceutical, Fraunhofer IGB, Fred Hutchinson Cancer Research Center, French National Blood Service, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Fujifilm, FUJIFILM Cellular Dynamics, Fujifilm Diosynth Biotechnologies, FutureGen Biopharm, Gadeta, Gaia, Galapagos, Gamida Cell, Gamma Biosciences, GammaDelta Therapeutics, GC Cell, GC LabCell, GE Healthcare, Gemelli Teaching Hospital, GEMoaB, GenCure, GeneFab, Genenta Science, Genentech, Generate Biomedicines, Generation Bio, Generex Biotechnology, Genezen, GenScript Biotech, GenScript ProBio, GentiBio, Germfree, Ghent University, Gicell, GigaMune, Gilead Sciences, Ginkgo BioWorks, Gladstone Institutes, Glycostem Therapeutics, Glycotope Biotechnology, Glytherix, Golden Meditech, Goliver Therapeutics, Government of Ireland, Gracell Biotechnologies, Green Cross LabCell, Gritstone Bio, Grunenthal, GSK, GT Biopharma, Guangzhou Fanen Biotechnology, Guangzhou Xiangxue Pharmaceutical, Hadassah Medical Center, HaemaLogiX, HanAll Pharmaceuticals, Hangzhou CNK Therapeutics, Hannover Medical School, Hanuman Pelican, Harbour Biomed, Harvard University, HCW Biologics, Healios K.K., Heartseed, Heat Biologics, HebeCell, HekaBio, Helix BioPharma, Helmholtz Zentrum Munchen, Hemogenyx, HepaTx, HiFiBio, Hitachi, Hitachi Chemical, Hitech Health, HK inno.N, Hoba Therapeutics, Hong Kong Baptist University, Hopstem Biotechnology, Horizon Discovery, Horizon Europe, Houston Methodist Research Institute, Huadong Medicine, Humanigen, Hypertrust, IASO Biotherapeutics, Iaso Pharmaceuticals, Imagine Pharmaceuticals, Immatics Biotechnologies, Immix Biopharma, ImmPACT Bio, Immunai, Immunicum, ImmunityBio, ImmunoCellular Therapeutics, ImmunoChina Pharmaceuticals, Immunomic Therapeutics, ImmunoScape, ImmunXperts, Immusoft, Immusol, Imperial College London, Implant Therapeutics, Imugene, IMV, Inceptor Bio, Incyte, Indapta Therapeutics, Indee Labs, Inhibrx, INmune Bio, Innate Pharma, InnDura Therapeutics, InnoBation, Innovare, Innovate UK, Innovative Cellular Therapeutics, Innovent Biologics, Inserm Transfert, Institute of Cancer Research, Institute of Endocrinology, Metabolism, and Reproduction, Integra Therapeutics, Intellia Therapeutics, International Society for Cellular Therapy, Intima Bioscience, Intrexon, Invectys, Invetech, INVO Bioscience, Iovance Biotherapeutics, I Peace, IQVIA, Isogenica, IsoPlexis, Israeli National Authority for Technological Innovation, Itochu, Ixaka, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Pharmaceutica NV, jCyte, Johns Hopkins University, Josep Carreras Leukaemia Research Institute, JSR, Juno Therapeutics, Jura Bio, Juvenile Diabetes Research Foundation, Juventas Therapeutics, JW Therapeutics, Kadimastem, Karolinska Institute, Karolinska University Hospital, Kelonia Therapeutics, Kennedy Institute of Rheumatology, Kentucky Organ Donor Affiliates, Kiadis Pharma, Kidswell Bio, Kincell Bio, Kinesiometrics, Kings College London, Kiromic Biopharma, Kite Pharma, Kleo Pharmaceuticals, Kolon Life Science, Korea-Israel Industrial R&D Foundation, KromaTiD, KSQ Therapeutics, Kytopen, Kyverna Therapeutics, L7 Informatics, LabConnect, Laboratory Corporation of America, Landmark Bio, Lee Moffitt Cancer Center, Legend Biotech, Leibniz-Institut fur Molekulare Pharmakologie, Leiden University, LEITAT, Les Laboratoires Servier, Leucid Bio, Leukemia & Lymphoma Society, LG Chem, LG Life Sciences, LifeLiver, LIfT BioSciences, Likarda, Lineage Cell Therapeutics, Link Health, Lion TCR, Locate Therapeutics, Logomix, Longeveron, Lonza, Lubeck Institute of Experimental Dermatology, Luminary Therapeutics, Lund University, Lung Biotechnology, Lupagen, Lupus Therapeutics, Luye Pharma Group, Lyell Immunopharma, LyGenesis, Lykan Bioscience, Lytix Biopharma, MabVax Therapeutics, Macomics, Magenta Therapeutics, Magnetic Insight, MainPointe, Mallinckrodt Pharmaceuticals, MangoGen Pharma, Marasco Laboratory, Marken, Marker Therapeutics, Mark Foundation for Cancer Research, Maryland Stem Cell Research Fund, Massachusetts General Hospital, Massachusetts Institute of Technology, Mass General Brigham, MaSTherCell, Maverick Therapeutics, Max-Delbruck Center for Molecular Medicine, Maxcyte, Mayo Clinic, McKesson, MCQ Instruments, MD Anderson Cancer Center, MDimune, Medac, Medical University of Graz, Medigen Biotechnology, MediGene, Medigen Vaccine Biologics, MED Institute, Medipal Holdings, MediSix Therapeutics, Memorial Sloan Kettering Cancer Center, Mendus, Merck and Co, Merck KGaA, Mesoblast, Metagenomi, Michael J Fox Foundation, Michal Morrison, MIGAL Galilee Research Institute, MilliporeSigma, Miltenyi Biotec, Minaris Regenerative Medicine, Minerva Biotechnologies, MiNK Therapeutics, Minovia Therapeutics, Mission Bio, Mitsubishi Tanabe Pharma, Modalis Therapeutics, Moderna, MolMed, Monarch Biosciences, Monomer Bio, Morgenesis, Mount Sinai Medical Center, Multimmune, Multiple Myeloma Research Foundation, Multiply Labs, Mundipharma, Mustang Bio, Myeloid Therapeutics, myNEO, Namocell, NanoString Technologies, NantKwest, NantOmics, NASA, National Cancer Institute, National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute of Allergy and Infectious Diseases, National Institute of Molecular Genetics, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institutes of Health, National Research Council of Canada, National Resilience, National Stem Cell Foundation, National University of Ireland, Galway (NUI Galway), National University of Singapore, Natural Sciences and  Engineering Research Council of Canada, NAYA Biosciences, Ncardia, NEC, Nektar Therapeutics, Neogene Therapeutics, NeoImmuneTech, Neon Therapeutics, Netherlands Cancer Institute, Neukio Biotherapeutics, Neurgain Technologies, Neurona Therapeutics, Neurophth Therapeutics, New Jersey Innovation Institute, New York Blood Center, New York Presbyterian/Columbia, Nexcella, Nexel, Neximmune, Next&Bio, Next Generation Manufacturing Canada, Nippon Shinyaku, Nkarta Therapeutics, NKGen Biotech, NKMax America, Nohla Therapeutics, Noile-Immune Biotech, Nordic Nanovector, Northern RNA, Northwell Health, NorthX Biologics, Norwegian Research Council, Notch Therapeutics, Novartis, Novasep, NoveCite, Novellus Biopharma, Novellus Therapeutics, Novo Nordisk, Nucleus Biologics, Nvidia, NYU Langone Medical Center, Obsidian Therapeutics, Octomera, Ohio State University, OmniaBio, Oncora Medical, OncoSec Medical, Oncternal Therapeutics, ONI, oNKo-innate, ONK Therapeutics, Ono Pharmaceutical, Onward Therapeutics, Opsis Therapeutics, Optieum Biotechnologies, Orca Bio, Orchard Therapeutics, Orgenesis, Ori Biotech, ORIG3N, Ortho Regenerative Technologies, Ospedale San Raffaele, Oswaldo Cruz Foundation (Fiocruz), Outpace Bio, Overland Pharmaceuticals, Oxford BioMedica, Oxford Genetics, OZ Biosciences, PACT Pharma, Palantir, Pall Corporation, Pan American Cancer Treatment Centers, Panbela Therapeutics, panCELLa, Pancryos, Papyrus Therapeutics, Parkinsons Disease Foundation, PDC*line Pharma, PDS Biotechnology, Penn Medicine, PersonGen BioTherapeutics, Peter MacCallum Cancer Institute, Pfizer, Phanes Therapeutics, PharmaCyte Biotech, PharmaEssentia, Pharmsynthez, Phenomic AI, Phio Pharmaceuticals, PhoreMost, Pierre Fabre, Plasticell, Platelet BioGenesis, Pluri, Pluristem Therapeutics, Pluristyx, Pompeu Fabra University, Portage Biotech, Poseida Therapeutics, Precision BioSciences, Precision NanoSystems, Pregene Biopharma, Prime Medicine, ProBioGen, ProMab Biotechnologies, Promethera Biosciences, Propagenix, ProteinTech, Proteona, ProteoNic, Provecs Medical, Providence Cancer Institute, Pure MHC, Q-Gen Cell Therapeutics, Qilu Pharmaceutical, Q Therapeutics, Quebec Consortium for Drug Discovery, Queen Mary University of London, Queensland Institute of Medical Research (QIMR), Quell Therapeutics, R4D Biotech, Refuge Biotechnologies, Regen BioPharma, Regeneron Pharmaceuticals, Regenexx, ReNeuron, Replay, Replicel Life Sciences, ReproCell, Research Institute of the Hospital Universitari Vall d'Hebron, Resilience, Resolution Therapeutics, Rexgenero, Rice University, Ricoh, Rigenerand, RIKEN Center for Integrative Medical Sciences, RIKEN Yokohama Institute Omics Science Center, Rivaara Immune, Roche, Rockland Immunochemicals, RoosterBio, Roswell Park Cancer Institute, Rubius Therapeutics, Rune Labs, Rutgers University, RxCell, RXi Pharmaceuticals, Sana Biotechnology, Sangamo Therapeutics, Sanofi, San Raffaele Scientific Institute, Santen Pharmaceutical, Sarah Cannon Research Institute, Sartorius, SAVSU Technologies, ScaleReady, Scribe Therapeutics, Scripps Research Institute, SCTbio, Seattle Children's Hospital, Seattle Children's Therapeutics, Seattle Childrens Research Institute, Secant Medical, Selexis, Senti Biosciences, SeQure Dx, Seraxis, Sernova, Serotiny, Sexton Biotechnologies, Shibuya Kogyo, Shinshu University, Shire Pharmaceuticals, Shoreline Biosciences, Showa Denko, Sigilon Therapeutics, Simcha Therapeutics, Singapore Eye Research Institute (SERI), Sinorda Biomedicine, Sirion Biotech, Smart Immune, Solentim, Sonnet BioTherapeutics, Sonoma BioTherapeutics, Sorrento Therapeutics, Sosei, Spanish State Research Agency, SparX Biopharmaceutical, Sphere Fluidics, SpringWorks Therapeutics, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, StemCardia, Stemcell Technologies, SUDA Pharmaceuticals, SunTerra Biotechnology, Supercell Biotechnology, Surrozen, Suzhou Porton Advanced Solutions, Syena, Symbasis, Symbiotix Biotherapies, Synlogic, Synova Healthcare, Synthego, T-Cure Bioscience, T-MAXIMUM Biotech, Tactiva Therapeutics, TaiwanBio Therapeutics, Takara Bio, Takeda Pharmaceutical, Takeda Ventures, Talaris Therapeutics, Targovax, Tasly Pharmaceuticals, TC BioPharm, TCR2 Therapeutics, Tel Aviv Sourasky Medical Center, TeneoBio, Terumo Blood and Cell Technologies, Tessa Therapeutics, Tevogen Bio, Texcell, TGen Drug Development, TG Therapeutics, The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, Therabest, Theracell, Therapeutic Solutions International, Theravectys, The Regents of the University of California, Thermo Fisher Scientific, ThinkCyte, Thomas Jefferson University, TissueGene, Tiziana Life Sciences, T Med, Tmunity Therapeutics, TNK Therapeutics, TOMI Environmental Solutions, Torque Therapeutics, Trakcel, Transgene, TreeFrog Therapeutics, Trinity College Dublin, Triumvira Immunologics, Truveta, TScan Therapeutics, Turnstone Biologics, Twist Bioscience, TxCell, UCL Business, UGA Biopharma, Umoja Biopharma, United Therapeutics, Universal Cells, Universite Laval, University College London, University Health Network, University Medical Center Groningen, University Medical Center Utrecht, University of Barcelona, University of Birmingham, University of British Columbia, University of California, Davis, University of California, San Diego, University of California Irvine, University of California San Francisco, University of California Santa Barbara, University of Colorado, University of Edinburgh, University of Heidelberg, University of Lausanne, University of Louisville, University of Minnesota, University of Montreal, University of North Carolina, University of North Texas Health Science Center, University of Nottingham, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Quebec, University of Sheffield, University of South Australia, University of Technology Sydney, University of Tennessee, University of Toronto, University of Victoria-Genome British Columbia Proteomics Centre, University Pierre Marie Curie, US Army, Utrecht University, Valitacell, Valo Therapeutics, Vaximm, Vedanta Biosciences, Velabs Therapeutics, Veltmeyer MD, Vericel, Verily, Verismo Therapeutics, Vertex Pharmaceuticals, ViaCyte, VIB, Victoria University, Vineti, Viracta Therapeutics, ViraCyte, Vir Biotechnology, Virion Therapeutics, Viroclinics Biosciences, Vision Care Group, Vitruvian Networks, Vittoria Biotherapeutics, VolitionRX, Vor Biopharma, Vycellix, Vyriad, Wake Forest University, Walking Fish Therapeutics, Washington University in St Louis, Weill Cornell Medical College, Whitehead Institute, WindMIL Therapeutics, Wisconsin Alumni Research Foundation, Wiseman Cancer Research Foundation, Wistar Institute, W L Gore, WUGEN, Wuxi Apptec Laboratory Services, Xcell Biosciences, Xenetic Biosciences, Xilio Therapeutics, XNK Therapeutics, Xyphos Biosciences, Y-Biologics, Yinjia Biosciences, YOFOTO (China) Health Industry, Yufan Biotechnologies, YUMAB, Zelluna Immunotherapy, Ziopharm Oncology

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.